The costs and inequities of precision medicine for patients with prostate cancer: A call to action.
Urol Oncol
; 41(9): 369-375, 2023 09.
Article
in En
| MEDLINE
| ID: mdl-37164775
ABSTRACT
Financial toxicity is a growing problem in the delivery of cancer care and contributes to inequities in outcomes across the cancer care continuum. Racial/ethnic inequities in prostate cancer, the most common cancer diagnosed in men, are well described, and threaten to widen in the era of precision oncology given the numerous structural barriers to accessing novel diagnostic studies and treatments, particularly for Black men. Gaps in insurance coverage and cost sharing are 2 such structural barriers that can perpetuate inequities in screening, diagnostic workup, guideline-concordant treatment, symptom management, survivorship, and access to clinical trials. Mitigating these barriers will be key to achieving equity in prostate cancer care, and will require a multi-pronged approach from policymakers, health systems, and individual providers. This narrative review will describe the current state of financial toxicity in prostate cancer care and its role in perpetuating racial inequities in the era of precision oncology.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Prostatic Neoplasms
/
Black or African American
/
Healthcare Disparities
/
Precision Medicine
/
Health Services Accessibility
Type of study:
Diagnostic_studies
/
Guideline
/
Health_economic_evaluation
/
Prognostic_studies
Aspects:
Determinantes_sociais_saude
Limits:
Humans
/
Male
Language:
En
Journal:
Urol Oncol
Journal subject:
NEOPLASIAS
/
UROLOGIA
Year:
2023
Document type:
Article